Your Shopping Cart Is Empty
| Report Code: A06114 | Sep 2020 | Pages: 275 | ||
| Tables: 318 | Charts: 39 |
| |
The global Covid-19 diagnostics market generated $73.19 million in the first quarter of 2020, and is anticipated to generate $9,948.19 million in the fourth quarter of 2020. By the end of year 2020, global Covid-19 diagnostics market size is anticipated to reach $17,203.38 million. Currently, world is facing a pandemic situation due to corona virus outbreak, which started back in December 2019, in Wuhan city of China. Covid-19 is an infectious disease caused by a newly discovered coronavirus. The name Covid-19 depicts belonging of the virus to corona virus family, with its first human interaction noticed in 2019. Further, SARS-CoV-2 is a novel strain of coronavirus that has not been previously identified in humans. Corona virus is the term coined to the family of viruses that transmit between animals and humans thus are also known as zoonotic viruses. Moreover, as of 27th March, 2020 the virus outbreak has been confirmed in six continents and more than 197 countries. As per the World Health Organization (WHO), common symptoms of Covid-19 infection include fever, tiredness, and dry cough. In addition, other symptoms of the disease include shortness of breath, sore throat, aches and pains, and diarrhea in few cases, as well as nausea or a runny nose. Moreover, this infection may spread from one person to other person via saliva droplets or discharge from nose, when an infected person coughs or sneezes. The time from exposure of a person to Covid-19 to onset of symptoms is generally between two to fourteen days, with an average of five days.
At present, the most widely used diagnostic test for detection of Covid-19 is reverse transcriptase PCR or RT PCR. PCR is recognized as the gold standard for diagnosis of various infectious agents. The technique has an advantage that the primers required for performing such tests can be produced with relative speed. Moreover, multiplex RT-PCR that has the capability of performing multiple target sequences simultaneously are the most preferred diagnostic tests for Covid-19. In addition, leading manufacturers of diagnostic kits such as Roche Diagnostics, Thermo Fisher Scientific, and Quest Diagnostics are significantly increasing up their capacity to perform such tests by rolling out automated SARS-CoV-2 testing systems. However, few companies such as SureScreen are focusing towards developing rapid immunoassay tests for Covid-19 diagnosis.
Â
The major factors that drive the covid-19 market growth include significant increase in patient population across the globe and immense need of rapid diagnostics. Covid-19 has been declared as a pandemic by WHO. On 26 March, 2020, as per WHO, the positive cases of covid-19 across the globe rose to 416,686 with 18,589 deaths. In addition, unavailability of specific medicine or a vaccine propels the covid-19 diagnostics market growth. However, lack of awareness among developing countries regarding the necessary precautions to be taken and dearth of medical professionals that have sufficient knowledge regarding the use of diagnostic kits for novel covid-19 are the major factors anticipated to hamper the growth of covid-19 diagnostics market. On the contrary, leading manufacturers of diagnostic kits can get benefited with several lucrative opportunities by developing rapid diagnostic kits. Further, various local players are also seeking immense opportunities by developing diagnostic kits and assays. For instance, Mylab, India has received approval by the Drug Controller of India for Covid-19 diagnostic kit, after the National Institute of Virology validated its test.
The Covid-19 diagnostics market is segmented on the basis of product, technology, end-users, and region. By product, it is categorized into PCR Kits, POC (point of contact) Kits and immune-assay. By technology, it is segmented into PCR and immunoassay. By end-users it is segmented into hospitals, physician's office & urgent care clinics and diagnostic labs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of technology, the PCR segment accounted for 80% of the total share in 2020 and is expected to exhibit a prominent growth rate in the near future, owing to its increased demand for diagnosis of coronavirus patients. In addition PCR is considered as a gold standard in terms of diagnosis of new virus infections. However, immunoassay segment is anticipated to grow at the fastest growth rate during the forecast period. This is attributed to the increased demand for rapid immunoassay tests for disease diagnosis. Many immunoassay test kits are being developed for the confirmation of Sars Cov 2 infections. For instance, qSARS-CoV-2 IgG/IgMtest developed by Cellex Inc.
By end user, the diagnosis labs segment is anticipated to dominate the Covid-19 diagnostics market in 2020, and continue to maintain its dominance throughout the forecast period. This is attributed to the fact that PCR test procedures require a laboratory to be processed as it includes the usage of various kinds of reagents and other instruments as well.Â
Key companies working towards the development of rapid diagnostic kits for Covid-19 include F. Hoffmann-La Roche AG, Seegene Inc., Cepheid, Mylab Lifesolutions Pvt. Ltd., SureScreen Diagnostics Ltd, Cellex Inc., Genematrix, Thermo Fisher Scientific, Inc.and Robert Bosch GmbH among others.
Key Benefits For Stakeholders
Covid-19 Diagnostics Market Report Highlights
| Aspects | Details |
|---|---|
| By Technology |
|
| By Product |
|
| By End User |
|
| By Region |
|
| Key Market Players | CELLEX INCORPORATED, THERMO FISHER SCIENTIFIC, INC., CEPHEID, F. HOFFMANN-LA ROCHE LTD., QUEST DIAGNOSTICS INCORPORATED, LABORATORY CORP OF AMERICA HOLDINGS, SEEGENE INC., MYLABDISCOVERY SOLUTIONS PVT. LTD., ABBOTT LABORATORIES, HOLOGIC, INC. |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Porter's five forces analysis
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Significant increase in incidences of COVID-19 infection
3.3.1.2.Unavailability of specific medicines/ vaccines
3.3.2.Restraints
3.3.2.1.Lack of COVID-19 diagnostic kits
3.3.3.Opportunity
3.3.3.1.Growth opportunities in emerging economies
3.4.Insights on antigen-based testing
3.5.Market share analysis
CHAPTER 4:COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
4.1.Overview
4.1.1.Approved COVID-19 Diagnostic Products
4.1.2.Market size and forecast, by technology
4.2.Molecular assay
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.3.Immunoassay/Serology
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
CHAPTER 5:COVID-19 DIAGNOSTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast, by product
5.2.PCR Kits
5.2.1.Market size and forecast, by region
5.3.Immunoassay test
5.3.1.Market size and forecast, by region
5.4.POC (Point -of-care) test
5.4.1.Market size and forecast, by region
CHAPTER 6:COVID-19 DIAGNOSTICS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast, by end user
6.2.Hospitals
6.2.1.Market size and forecast, by region
6.3.Diagnostic laboratories
6.3.1.Market size and forecast, by region
6.4.Physician offices & urgent care clinics
6.4.1.Market size and forecast, by region
CHAPTER 7:COVID-19 DIAGNOSTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S. market size and forecast, by technology
7.2.2.2.U.S. market size and forecast, by product
7.2.2.3.U.S. market size and forecast, by end user
7.2.2.4.Canada market size and forecast, by technology
7.2.2.5.Canada market size and forecast, by product
7.2.2.6.Canada. market size and forecast, by end user
7.2.2.7.Mexico market size and forecast, by technology
7.2.2.8.Mexico market size and forecast, by product
7.2.2.9.Mexico. market size and forecast, by end user
7.3.Europe
7.3.1.Key market trends
7.3.2.Market size and forecast, by country
7.3.2.1.France market size and forecast, by technology
7.3.2.2.France market size and forecast, by product
7.3.2.3.France market size and forecast, by end user
7.3.2.4.UK market size and forecast, by technology
7.3.2.5.UK market size and forecast, by product
7.3.2.6.UK. market size and forecast, by end user
7.3.2.7.Germany market size and forecast, by technology
7.3.2.8.Germany market size and forecast, by product
7.3.2.9.Germany market size and forecast, by end user
7.3.2.10.Spain market size and forecast, by technology
7.3.2.11.Spain market size and forecast, by product
7.3.2.12.Spain market size and forecast, by end user
7.3.2.13.Italy market size and forecast, by technology
7.3.2.14.Italy market size and forecast, by product
7.3.2.15.Italy market size and forecast, by end user
7.3.2.16.Austria market size and forecast, by technology
7.3.2.17.Austria market size and forecast, by product
7.3.2.18.Austria market size and forecast, by end user
7.3.2.19.Estonia market size and forecast, by technology
7.3.2.20.Estonia market size and forecast, by product
7.3.2.21.Estonia market size and forecast, by end user
7.3.2.22.Czech Republic market size and forecast, by technology
7.3.2.23.Czech Republic market size and forecast, by product
7.3.2.24.Czech Republic market size and forecast, by end user
7.3.2.25.Rest of Europe market size and forecast, by technology
7.3.2.26.Rest of Europe market size and forecast, by product
7.3.2.27.Rest of Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.1.Japan market size and forecast, by technology
7.4.3.2.Japan market size and forecast, by product
7.4.3.3.Japan market size and forecast, by end user
7.4.3.4.China market size and forecast, by technology
7.4.3.5.China market size and forecast, by product
7.4.3.6.China market size and forecast, by end user
7.4.3.7.India market size and forecast, by technology
7.4.3.8.India market size and forecast, by product
7.4.3.9.India market size and forecast, by end user
7.4.3.10.Australia market size and forecast, by technology
7.4.3.11.Australia market size and forecast, by product
7.4.3.12.Australia market size and forecast, by end user
7.4.3.13.South Korea market size and forecast, by technology
7.4.3.14.South Korea market size and forecast, by product
7.4.3.15.South Korea market size and forecast, by end user
7.4.3.16.Thailand market size and forecast, by technology
7.4.3.17.Thailand market size and forecast, by product
7.4.3.18.Thailand market size and forecast, by end user
7.4.3.19.Malaysia market size and forecast, by technology
7.4.3.20.Malaysia market size and forecast, by product
7.4.3.21.Malaysia market size and forecast, by end user
7.4.3.22.Rest of Asia-Pacific market size and forecast, by technology
7.4.3.23.Rest of Asia-Pacific market size and forecast, by product
7.4.3.24.Rest of Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil market size and forecast, by technology
7.5.2.2.Brazil market size and forecast, by product
7.5.2.3.Brazil market size and forecast, by end user
7.5.2.4.South Africa market size and forecast, by technology
7.5.2.5.South Africa market size and forecast, by product
7.5.2.6.South Africa market size and forecast, by end user
7.5.2.7.Saudi Arabia market size and forecast, by technology
7.5.2.8.Saudi Arabia market size and forecast, by product
7.5.2.9.Saudi Arabia market size and forecast, by end user
7.5.2.10.Israel market size and forecast, by technology
7.5.2.11.Israel market size and forecast, by product
7.5.2.12.Israel market size and forecast, by end user
7.5.2.13.Rest of LAMEA market size and forecast, by technology
7.5.2.14.Rest of LAMEA market size and forecast, by product
7.5.2.15.Rest of LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.CELLEX INCORPORATED
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.CEPHEID
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.F. HOFFMANN-LA ROCHE LTD.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance.
8.4.6.Key strategic moves and developments
8.5.HOLOGIC, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.LABORATORY CORP OF AMERICA HOLDINGS
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.MYLABDISCOVERY SOLUTIONS PVT. LTD.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.QUEST DIAGNOSTICS INCORPORATED
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.SEEGENE INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.ANTIGEN-BASED TEST KIT AND MANUFACTURERS
TABLE 02.APPROVED COVID-19 DIAGNOSTIC PRODUCTS
TABLE 03.COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 04.COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 05.COVID-19 DIAGNOSTICS MARKET,BY TECHNOLOGY, 2022 ($MILLION)
TABLE 06.COVID-19 DIAGNOSTICS MARKET FOR MOLECULAR ASSAY, BY REGION, 2020 ($MILLION)
TABLE 07.COVID-19 DIAGNOSTICS MARKET FOR MOLECULAR ASSAY, BY REGION, 2021 ($MILLION)
TABLE 08.COVID-19 DIAGNOSTICS MARKET FOR MOLECULAR ASSAY, BY REGION, 2022 ($MILLION)
TABLE 09.COVID-19 DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2020 ($MILLION)
TABLE 10.COVID-19 DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2021 ($MILLION)
TABLE 11.COVID-19 DIAGNOSTICS MARKET FOR IMMUNOASSAY, BY REGION, 2022 ($MILLION)
TABLE 12.COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 13.COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 14.COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 15.COVID-19 DIAGNOSTICS MARKET, FOR PCR KITS, BY REGION, 2020 ($MILLION)
TABLE 16.COVID-19 DIAGNOSTICS MARKET, FOR PCR KITS, BY REGION, 2021 ($MILLION)
TABLE 17.COVID-19 DIAGNOSTICS MARKET, FOR PCR KITS, BY REGION, 2022 ($MILLION)
TABLE 18.COVID-19 DIAGNOSTICS MARKET FOR IMMUNOASSAY TEST, BY REGION, 2020 ($MILLION)
TABLE 19.COVID-19 DIAGNOSTICS MARKET, FOR IMMUNOASSAY TEST, BY REGION, 2021 ($MILLION)
TABLE 20.COVID-19 DIAGNOSTICS MARKET, FOR IMMUNOASSAY TEST, BY REGION, 2022 ($MILLION)
TABLE 21.COVID-19 DIAGNOSTICS MARKET FOR POC TEST KITS, BY REGION, 2020 ($MILLION)
TABLE 22.COVID-19 DIAGNOSTICS MARKET, FOR POC TEST KITS, BY REGION, 2021 ($MILLION)
TABLE 23.COVID-19 DIAGNOSTICS MARKET, FOR POC TEST KITS, BY REGION, 2022 ($MILLION)
TABLE 24.COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 25.COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 26.COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 27.COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2020 ($MILLION)
TABLE 28.COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2021 ($MILLION)
TABLE 29.COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2022 ($MILLION)
TABLE 30.COVID-19 DIAGNOSTICS MARKET, FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020 ($MILLION)
TABLE 31.COVID-19 DIAGNOSTICS MARKET, FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021 ($MILLION)
TABLE 32.COVID-19 DIAGNOSTICS MARKET, FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022 ($MILLION)
TABLE 33.COVID-19 DIAGNOSTICS MARKET, FOR PHYSICIAN OFFICES & URGENT CARE CLINICS, BY REGION, 2020 ($MILLION)
TABLE 34.COVID-19 DIAGNOSTICS MARKET, FOR PHYSICIAN OFFICES & URGENT CARE CLINICS, BY REGION, 2021 ($MILLION)
TABLE 35.COVID-19 DIAGNOSTICS MARKET, FOR PHYSICIAN OFFICES & URGENT CARE CLINICS, BY REGION, 2022 ($MILLION)
TABLE 36.COVID-19 DIAGNOSTICS MARKET, BY REGION, 2020–2022 ($MILLION)
TABLE 37.COVID-19 DIAGNOSTICS MARKET, BY REGION, 2020–2022 (NUMBER OF TESTS)
TABLE 38.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
TABLE 39.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
TABLE 40.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
TABLE 41.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
TABLE 42.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
TABLE 43.NORTH AMERICA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (NUMBER OF TESTS)
TABLE 44.U.S. COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 45.U.S. COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 46.U.S. COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 47.U.S. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 48.U.S. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 49.U.S. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 50.U.S. COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 51.U.S. COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 52.U.S. COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 53.CANADA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 54.CANADA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 55.CANADA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 56.CANADA. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 57.CANADA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 58.CANADA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 59.CANADA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 60.CANADA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 61.CANADA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 62.MEXICO COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 63.MEXICO COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 64.MEXICO COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 65.MEXICO. COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 66.MEXICO COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 67.MEXICO COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 68.MEXICO COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 69.MEXICO COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 70.MEXICO COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 71.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
TABLE 72.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
TABLE 73.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
TABLE 74.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
TABLE 75.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
TABLE 76.EUROPE COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
TABLE 77.FRANCE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 78.FRANCE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 79.FRANCE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 80.FRANCE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 81.FRANCE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 82.FRANCE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 83.FRANCE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 84.FRANCE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 85.FRANCE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 86.UK COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 87.UK COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 88.UK COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 89.UK COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 90.UK COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 91.UK COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 92.UK COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 93.UK COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 94.UK DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 95.GERMANY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 96.GERMANY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 97.GERMANY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 98.GERMANY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 99.GERMANY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 100.GERMANY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 101.GERMANY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 102.GERMANY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 103.GERMANY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 104.SPAIN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 105.SPAIN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 106.SPAIN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 107.SPAIN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 108.SPAIN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 109.SPAIN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 110.SPAIN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 111.SPAIN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 112.SPAIN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 113.ITALY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 114.ITALY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 115.ITALY COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 116.ITALY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 117.ITALY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 118.ITALY COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 119.ITALY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 120.ITALY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 121.ITALY COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 122.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 123.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 124.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 125.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 126.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 127.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 128.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 129.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 130.AUSTRIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 131.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 132.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 133.ESTONIACOVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 134.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 135.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 136.ESTONIACOVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 137.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 138.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 139.ESTONIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 140.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 141.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 142.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 143.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 144.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 145.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 146.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 147.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 148.CZECH REPUBLIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 149.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 150.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 151.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 152.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 153.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 154.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 155.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 156.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 157.REST OF EUROPE COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 158.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020($MILLION)
TABLE 159.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 (NUMBER OF TESTS)
TABLE 160.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021($MILLION)
TABLE 161.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 (NUMBER OF TESTS)
TABLE 162.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022($MILLION)
TABLE 163.ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (NUMBER OF TESTS)
TABLE 164.JAPAN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 165.JAPAN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 166.JAPAN COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 167.JAPAN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 168.JAPAN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 169.JAPAN COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 170.JAPAN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 171.JAPAN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 172.JAPAN COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 173.CHINA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 174.CHINA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 175.CHINA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 176.CHINA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 177.CHINA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 178.CHINA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 179.CHINA DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 180.CHINA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 181.CHINA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 182.INDIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 183.INDIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 184.INDIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 185.INDIACOVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 186.INDIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 187.INDIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 188.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 189.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 190.INDIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 191.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 192.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 193.AUSTRALIA MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 194.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 195.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 196.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 197.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 198.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 199.AUSTRALIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 200.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 201.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 202.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 203.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 204.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 205.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 206.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 207.SOUTH KOREACOVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 208.SOUTH KOREA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 209.THAILAND COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 210.THAILAND COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 211.THAILAND COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 212.THAILAND COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 213.THAILAND COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 214.THAILAND COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 215.THAILAND COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 216.THAILAND COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 217.THAILAND COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 218.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 219.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 220.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 221.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 222.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 223.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 224.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 225.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 226.MALAYSIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 227.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 228.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 229.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 230.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 231.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 232.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 233.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 234.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 235.REST OF ASIA-PACIFIC COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 236.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020 ($MILLION)
TABLE 237.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2020(NUMBER OF TESTS)
TABLE 238.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021 ($MILLION)
TABLE 239.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2021(NUMBER OF TESTS)
TABLE 240.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 ($MILLION)
TABLE 241.LAMEA COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022(NUMBER OF TESTS)
TABLE 242.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 243.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 244.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 245.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 246.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 247.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 248.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 249.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 250.BRAZIL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 251.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 252.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 253.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 254.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 255.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 256.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 257.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 258.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 259.SOUTH AFRICA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 260.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 261.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 262.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 263.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 264.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 265.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 266.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 267.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 268.SAUDI ARABIA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 269.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 270.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 271.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 272.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 273.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 274.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 275.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 276.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 277.ISRAEL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 278.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 ($MILLION)
TABLE 279.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 ($MILLION)
TABLE 280.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 ($MILLION)
TABLE 281.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2020 ($MILLION)
TABLE 282.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2021 ($MILLION)
TABLE 283.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY PRODUCT, 2022 ($MILLION)
TABLE 284.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2020 ($MILLION)
TABLE 285.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 ($MILLION)
TABLE 286.REST OF LAMEA COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 ($MILLION)
TABLE 287.ABBOTT: COMPANY SNAPSHOT
TABLE 288.ABBOTT: OERATING SEGMENT
TABLE 289.ABBOTT: PRODUCT PORTFOLIO
TABLE 290.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 291.CELLEX: COMPANY SNAPSHOT
TABLE 292.CELLEX: OPERATING SEGMENTS
TABLE 293.CELLEX: PRODUCT PORTFOLIO
TABLE 294.CELLEX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 295.CEPHEID: COMPANY SNAPSHOT
TABLE 296.CEPHEID: OPERATING BUSINESS SEGMENTS
TABLE 297.CEPHEID: PRODUCT PORTFOLIO
TABLE 298.ROCHE: COMPANY SNAPSHOT
TABLE 299.ROCHE: OPERATING SEGMENTS
TABLE 300.ROCHE: PRODUCT PORTFOLIO
TABLE 301.HOLOGIC: COMPANY SNAPSHOT
TABLE 302.HOLOGIC: OPERATING BUSINESS SEGMENTS
TABLE 303.HOLOGIC: PRODUCT PORTFOLIO
TABLE 304.LABCORP: COMPANY SNAPSHOT
TABLE 305.LABCORP: OPERATING SEGMENTS
TABLE 306.LABCORP: PRODUCT PORTFOLIO
TABLE 307.MYLAB: COMPANY SNAPSHOT
TABLE 308.MYLAB: PRODUCT SEGMENTS
TABLE 309.MYLAB: PRODUCT PORTFOLIO
TABLE 310.QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 311.QUEST DIAGNOSTICS: OPERATING BUSINESS SEGMENTS
TABLE 312.QUEST: PRODUCT PORTFOLIO
TABLE 313.SEEGENE: COMPANY SNAPSHOT
TABLE 314.SEEGENE: OPERATING SEGMENTS
TABLE 315.SEEGENE: PRODUCT PORTFOLIO
TABLE 316.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 317.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENTS
TABLE 318.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.COVID-19 DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 03.LOW BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTES
FIGURE 05.LOW-TO-MODERATE THREAT OF NEW ENTRANTS
FIGURE 06.HIGH COMPETITIVE RIVALARY
FIGURE 07.DRIVERS AND RESTRAINTS
FIGURE 08.MARKET SHARE ANALYSIS, MOLECULAR KITS
FIGURE 09.MARKET SHARE ANALYSIS, IMMUNOASSAY TEST
FIGURE 10.MARKET SHARE ANALYSIS, MOLECULAR POINT OF CARE KITS
FIGURE 11.MARKET SHARE ANALYSIS, NORTH AMERICA MOLECULAR KITS
FIGURE 12.MARKET SHARE ANALYSIS, NORTH AMERICA IMMUNOASSAY TEST
FIGURE 13.MARKET SHARE ANALYSIS, NORTH AMERICA MOLECULAR POINT OF CARE KITS
FIGURE 14.MARKET SHARE ANALYSIS, EUROPE MOLECULAR KITS
FIGURE 15.MARKET SHARE ANALYSIS, EUROPE IMMUNOASSAY TEST
FIGURE 16.MARKET SHARE ANALYSIS, EUROPE MOLECULAR POINT OF CARE KITS
FIGURE 17.MARKET SHARE ANALYSIS, ASIA-PACIFIC MOLECULAR KITS (RT PCR)
FIGURE 18.MARKET SHARE ANALYSIS, ASIA-PACIFIC IMMUNOASSAY TEST
FIGURE 19.MARKET SHARE ANALYSIS, ASIA-PACIFIC MOLECULAR POINT OF CARE KITS
FIGURE 20.MARKET SHARE ANALYSIS, LAMEA MOLECULAR KITS
FIGURE 21.MARKET SHARE ANALYSIS, LAMEA IMMUNOASSAY TEST
FIGURE 22.MARKET SHARE ANALYSIS, LAMEA MOLECULAR POINT OF CARE KITS
FIGURE 23.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 25.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 26.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.HOLOGIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.HOLOGIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.HOLOGIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.LABCORP: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.LABCORP: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 34.LABCORP: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 35.QUEST DIAGNOSTICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 37.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 38.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 39.THERMO FISHER SCIENTIFIC. REVENUE SHARE BY REGION, 2019 (%)
Covid-19 diagnosis is a contagious disease and is spreading across the globe with fast pace. Hence, there is an urgent requirement for the development of rapid diagnosis tests to prevent widespread of the disease. Moreover, significant ongoing researches are being conducted across the globe to develop rapid diagnosis test kits against Covid-19. Many leading as well small players are focusing toward the development of diagnosis kits that can verify coronavirus infection in its early stage. For instance, on March 12, 2020, Roche Diagnostics, a subsidiary of F. Hoffmann-La Roche AG, a Swiss multinational healthcare company, received the U.S. FDA Emergency Use Authorization for its novel coronavirus diagnostic test kit- Cobas SARS-CoV-2. In addition, an American company, Cepheid developed an automated molecular diagnostic test for qualitative detection of SARS-CoV-2, which has been approved by the U.S. FDA. The test is able to diagnose sars cov 2 infections in around 45 minutes. RT PCR is being considered as the gold standard for diagnosis of the new virus infection.
The Covid-19 diagnostics market is anticipated to witness steady growth during the forecast period, owing to rise in incidences across the globe, surge in diagnosis procedure being performed, and increase in research & development in the field of disease diagnosis. Moreover, increased initiatives to develop rapid diagnosis methods and medical devices for fast disease diagnosis contribute to the market growth
A. The total market value of Covid 19 Diagnostics Market is $17,203.38 million till the end of 2020.
A. The forcast period for Covid 19 Diagnostics Market is 2020 to 2022.
A. The market value of Covid 19 Diagnostics Market in 2020 is $17,203.38 million.
A. The base year is 2020 in Covid 19 Diagnostics Market
A. Top companies such as, F. Hoffmann-La Roche AG, Seegene Inc., Cepheid, Mylab Lifesolutions Pvt. Ltd., SureScreen Diagnostics Ltd, Thermo Fisher Scientific, Genematrix, and Robert Bosch GmbH among others.
A. Polymerase chain reaction (PCR) Kits segment is the most influencing segment owing to its increased demand for diagnosis of coronavirus patients.
A. The major factor that fuels the growth of the Covid 19 Diagnostics Market includes significant increase in patient population across the globe and immense need of rapid diagnostics. Covid-19 has been declared as a pandemic by WHO. In addition, unavailability of specific medicine or a vaccine propels the covid-19 diagnostics market growth.
A. No, there is no value chain analysis provided in the Covid 19 Diagnostics Market report
A. Covid-19 is an infectious disease caused by a newly discovered coronavirus. The name Covid-19 depicts belonging of the virus to corona virus family, with its first human interaction noticed in 2019.
A. At present, the most widely used diagnostic test for detection of Covid-19 is reverse transcriptase PCR or RT PCR. PCR is recognized as the gold standard for diagnosis of various infectious agents.
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report